Emerging Indications for Interventional Oncology: A Comprehensive Systematic Review of Image-Guided Thermal Ablation for Metastatic Non-cervical Lymph Node Disease.
Interventional oncology
Lymph node metastasis
Meta-analysis
Oligometastatic disease
Systematic review
Thermal ablation
Journal
Current oncology reports
ISSN: 1534-6269
Titre abrégé: Curr Oncol Rep
Pays: United States
ID NLM: 100888967
Informations de publication
Date de publication:
28 Oct 2024
28 Oct 2024
Historique:
accepted:
14
10
2024
medline:
28
10
2024
pubmed:
28
10
2024
entrez:
28
10
2024
Statut:
aheadofprint
Résumé
Lymphatic node metastatic disease encompasses a distinct oncological entity which has been associated with poor prognosis. Image-guided thermal ablation has recently been proposed as a safe and alternative treatment for these lesions. The aim of this systematic review is to evaluate the pooled safety and efficacy of thermal ablation techniques for the treatment of oligometastatic non-cervical lymph nodal disease. A systematic search of the three major databases (MEDLINE, EMBASE, and CENTRAL) from inception to 30 December 2023 was conducted according to the PRISMA Guidelines. Observational studies reporting technical success, complications and oncologic outcomes were included. Meta- analysis was performed by estimating the pooled incidence rates and risk ratios by fitting random-effect models. Overall, 8 studies were included, comprising of 225 patients and 305 ablated LNMs and a median follow-up of 12 months. The combined data analysis showed that technical success after thermal ablation was 98% (CI: 95%-99%), major complication rate was 1% (CI: 95%-99%), pooled overall response rate was 72% (CI: 54%-87%), local tumor progression rate was 18% (CI: 8%-33%) and disease-free survival rate was 68% (CI: 51%-81%). No difference between radiofrequency ablation and cryoablation was found for every outcome during subgroup analysis. Image-guided percutaneous thermal ablation (with either radiofrequency ablation or cryoablation) is safe and effective for the treatment of oligometastatic LMN disease, however further studies to confirm these findings are still needed.
Identifiants
pubmed: 39466479
doi: 10.1007/s11912-024-01616-4
pii: 10.1007/s11912-024-01616-4
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Christ SM, Heesen P, Muehlematter UJ, Pohl K, William Thiel G, Willmann J, et al. Recognition of and treatment recommendations for oligometastatic disease in multidisciplinary tumor boards. Clin Transl Radiat Oncol. 2023;38:123–9.
pubmed: 36420098
Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21:e18-28.
doi: 10.1016/S1470-2045(19)30718-1
pubmed: 31908301
Rees M, Tekkis PP, Welsh FKS, O’Rourke T, John TG. Evaluation of Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer. Ann Surg. 2008;247:125–35.
doi: 10.1097/SLA.0b013e31815aa2c2
pubmed: 18156932
Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8:378–82.
doi: 10.1038/nrclinonc.2011.44
pubmed: 21423255
Reyes DK, Pienta KJ. The biology and treatment of oligometastatic cancer. Oncotarget. 2015;6:8491–524.
doi: 10.18632/oncotarget.3455
pubmed: 25940699
pmcid: 4496163
Manabe Y, Shibamoto Y, Baba F, Murata R, Yanagi T, Hashizume C, et al. Radiotherapy for hilar or mediastinal lymph node metastases after definitive treatment with stereotactic body radiotherapy or surgery for stage I non-small cell lung cancer. Pract Radiat Oncol. 2012;2:e137–43.
doi: 10.1016/j.prro.2011.11.007
pubmed: 24674177
Huang F, Wu G, Yang K. Oligometastasis and oligo-recurrence: more than a mirage. Radiat Oncol. 2014;9:230.
doi: 10.1186/s13014-014-0230-6
pubmed: 25359216
pmcid: 4222373
Autrusseau P-A, Cazzato RL, Koch G, Ramamurthy N, Auloge P, De Marini P, et al. Freezing Nodal Disease: Local Control Following Percutaneous Image-Guided Cryoablation of Locoregional and Distant Lymph Node Oligometastases: A 10-Year, Single-Center Experience. J Vasc Interv Radiol. 2021;32:1435–44.
doi: 10.1016/j.jvir.2021.07.002
pubmed: 34271190
Tsoumakidou G, Mandralis K, Hocquelet A, Duran R, Denys A. Salvage Lymph-Node Percutaneous Cryoablation: Safety Profile and Oncologic Outcomes. Cardiovasc Intervent Radiol. 2020;43:264–72.
doi: 10.1007/s00270-019-02341-3
pubmed: 31591690
Filippiadis D, Charalampopoulos G, Tsochatzis A, Reppas L, Mazioti A, Kelekis A, et al. Feasibility and safety of percutaneous computed tomography guided radiofrequency ablation of lymph nodes in oligometastatic patients: a single center’s experience. Br J Radiol. 2021;94:20200445.
doi: 10.1259/bjr.20200445
pubmed: 33756082
pmcid: 8506176
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, The PRISMA, et al. statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:n71.
Higgins, J.P.T.: Thomas, J.: Chandler, J.: Cumpston, M.: Li, T.: Page, M.J.: Welch, V.A. (Eds.) Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (Updated August 2023). Cochrane. 2023. Available online: www.training.cochrane.org/handbook. Accessed on 30 November 2023.
Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;i4919. https://doi.org/10.1136/bmj.i4919
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
doi: 10.1186/1471-2288-14-135
pubmed: 25524443
pmcid: 4383202
Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, et al. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods. 2016;7:55–79.
doi: 10.1002/jrsm.1164
pubmed: 26332144
Chen Y, Chen D, Wang Y, Han Y. Using Freeman-Tukey Double Arcsine Transformation in Meta-analysis of Single Proportions. Aesthetic Plast Surg. 2023;47:83–4.
doi: 10.1007/s00266-022-02977-6
pubmed: 35764810
Fletcher J. What is heterogeneity and is it important? BMJ. 2007;334:94–6.
doi: 10.1136/bmj.39057.406644.68
pubmed: 17218716
pmcid: 1767262
Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: A practical tutorial. Evid Based Ment Health. 2019;22:153–60.
doi: 10.1136/ebmental-2019-300117
pubmed: 31563865
pmcid: 10231495
Hiraki T, Yasui K, Mimura H, Gobara H, Mukai T, Hase S, et al. Radiofrequency Ablation of Metastatic Mediastinal Lymph Nodes during Cooling and Temperature Monitoring of the Tracheal Mucosa to Prevent Thermal Tracheal Damage: Initial Experience. Radiology. 2005;237:1068–74.
doi: 10.1148/radiol.2373050234
pubmed: 16237146
Gao F, Gu Y, Huang J, Zhao M, Wu P. Radiofrequency Ablation of Retroperitoneal Metastatic Lymph Nodes from Hepatocellular Carcinoma. Acad Radiol. 2012;19:1035–40.
doi: 10.1016/j.acra.2012.04.003
pubmed: 22591723
Pan T, Xie Q-K, Lv N, Li X-S, Mu L-W, Wu P-H, et al. Percutaneous CT-guided Radiofrequency Ablation for Lymph Node Oligometastases from Hepatocellular Carcinoma: A Propensity Score–matching Analysis. Radiology. 2017;282:259–70.
doi: 10.1148/radiol.2016151807
pubmed: 27399327
Parvinian A, Schmitz JJ, Welch BT, Atwell TD, Morris JM, Woodrum DA, et al. A Single-Institution Experience in Percutaneous Image-Guided Cryoablation of Lymph Node Metastases. Am J Roentgenol. 2021;217:152–6.
doi: 10.2214/AJR.20.22861
Filippiadis DK, Pua U, Georgiadi E, Quek LHH, Kelekis A, How GY, et al. Percutaneous Ablation of Metastatic Lymph Nodes: An Insight from the Comparison of Efficacy and Safety Between Cryoablation and Radiofrequency Ablation. Cardiovasc Intervent Radiol. 2022;45:1134–40.
doi: 10.1007/s00270-022-03191-2
pubmed: 35680674
Mu L, Sun L, Pan T, Lyu N, Li S, Li X, et al. Percutaneous CT-guided radiofrequency ablation for patients with extrahepatic oligometastases of hepatocellular carcinoma: long-term results. Int J Hyperth. 2018;34:59–67.
doi: 10.1080/02656736.2017.1318332
Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.
doi: 10.1200/JCO.1995.13.1.8
pubmed: 7799047
Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer. JAMA Oncol. 2018;4:e173501.
doi: 10.1001/jamaoncol.2017.3501
pubmed: 28973074
Ruers T, Van Coevorden F, Punt CJA, Pierie J-PEN, Borel-Rinkes I, Ledermann JA, et al. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. JNCI: J Natl Cancer Inst. 2017;109:djx015.
doi: 10.1093/jnci/djx015
pubmed: 28376151
pmcid: 5408999
Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019;37:1558–65.
doi: 10.1200/JCO.19.00201
pubmed: 31067138
pmcid: 6599408
Ding Z, Chen J, Chen Z, Zeng X, Zheng P, Wang X, et al. Efficacy and Safety of Thermal Ablation for Treating Lymph Node Metastasis From Papillary Thyroid Carcinoma: A Systematic Review and Meta-Analysis. Front Oncol. 2022;12:738299.
doi: 10.3389/fonc.2022.738299
pubmed: 35433407
pmcid: 9010561
Franzese C, Badalamenti M, Comito T, Franceschini D, Clerici E, Navarria P, et al. Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatment’s intensification? Radiother Oncol. 2020;150:184–90.
doi: 10.1016/j.radonc.2020.06.029
pubmed: 32593644
Zeng Z-C, Tang Z-Y, Fan J, Qin L-X, Ye S-L, Zhou J, et al. Consideration of role of radiotherapy for lymph node metastases in patients with HCC: Retrospective analysis for prognostic factors from 125 patients. Int J Radiat Oncol Biol Phys. 2005;63:1067–76.
doi: 10.1016/j.ijrobp.2005.03.058
pubmed: 15913915
Russell CM, Espiritu PN, Kassouf W, Schwaab T, Buethe DD, Dhilon J, et al. Surgical Outcomes in the Management of Isolated Nodal Recurrences: A Multicenter, International Retrospective Cohort. J Urol. 2014;192:350–6.
doi: 10.1016/j.juro.2014.02.010
pubmed: 24530987
MacDermed DM, Weichselbaum RR, Salama JK. A rationale for the targeted treatment of oligometastases with radiotherapy. J Surg Oncol. 2008;98:202–6.
doi: 10.1002/jso.21102
pubmed: 18618604
Iezzi R, Gangi A, Posa A, Pua U, Liang P, Santos E, et al. Emerging Indications for Interventional Oncology: Expert Discussion on New Locoregional Treatments. Cancers (Basel). 2023;15:308.
doi: 10.3390/cancers15010308
pubmed: 36612304